HRP20190542T1 - Životinje s humaniziranim il-15 - Google Patents
Životinje s humaniziranim il-15 Download PDFInfo
- Publication number
- HRP20190542T1 HRP20190542T1 HRP20190542TT HRP20190542T HRP20190542T1 HR P20190542 T1 HRP20190542 T1 HR P20190542T1 HR P20190542T T HRP20190542T T HR P20190542TT HR P20190542 T HRP20190542 T HR P20190542T HR P20190542 T1 HRP20190542 T1 HR P20190542T1
- Authority
- HR
- Croatia
- Prior art keywords
- rodent
- gene
- humanized
- protein
- genetically modified
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 43
- 108090000172 Interleukin-15 Proteins 0.000 claims 43
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 241000283984 Rodentia Species 0.000 claims 36
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 9
- 102000056003 human IL15 Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 230000001105 regulatory effect Effects 0.000 claims 8
- 108700024394 Exon Proteins 0.000 claims 6
- 210000004698 lymphocyte Anatomy 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 101100179540 Homo sapiens IL15 gene Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Genetički modificirani glodavac, naznačen time što mu genom sadrži:
zamjenu na lokusu endogenog glodavačkog IL-15 od fragmenta glodavačkog genoma koji kodira zreli glodavački polipeptid IL-15 genomskim fragmentom gena za ljudski IL-15 koji kodira zreli ljudski polipeptid IL-15 kako bi se dobilo gen za humanizirani IL-15,
gdje gen za humanizirani IL-15 sadrži sve egzone koji ne kodiraju protein iz glodavačkog IL-15 i regulacijska područja uzvodno od prvog egzona koji kodira protein iz gena za glodavački IL-15, a eksprimiranje gena za humanizirani IL-15 je pod kontrolom navedenih regulacijskih područja, i
gdje gen za humanizirani IL-15 dovodi eksprimiranja proteina IL-15 koji kada je zreo je posve ljudski.
2. Genetički modificirani glodavac u skladu s patentnim zahtjevom 1, naznačen time što je miš ili štakor.
3. Postupak dobivanja genetički modificiranog glodavca, naznačen time što se sastoji u:
modificiranju genoma glodavca zamjenom fragmenta glodavačkog genoma koji kodira zreli glodavački polipeptid IL-15 na lokusu endogenog glodavačkog IL-15 genomskim fragmentom gena za ljudski IL-15 koji kodira zreli ljudski IL-15 polipeptid, kako bi se dobilo gen za humanizirani IL-15,
gdje gen za humanizirani IL-15 sadrži sve egzone koji ne kodiraju protein iz glodavačkog IL-15 i regulacijska područja uzvodno od prvog egzona koji kodira protein iz gena za glodavački IL-15, a eksprimiranje gena za humanizirani IL-15 je pod kontrolom navedenih regulacijskih područja, i
gdje gen za humanizirani IL-15 dovodi eksprimiranja proteina IL-15 koji kada je zreo je posve ljudski.
4. Postupak u skladu s patentnim zahtjevom 3, naznačen time što je genetički modificirani glodavac miš ili štakor.
5. Genetički modificirani glodavac, naznačen time što mu genom sadrži gen za humanizirani IL-15,
gdje gen za humanizirani IL-15 sadrži egzone ljudskog IL-15 koji kodiraju zreli protein, koji kodiraju protein koji sadrži polipeptidni slijed zrelog ljudskog IL-15,
gdje gen za humanizirani IL-15 sadrži sve egzone koji ne kodiraju protein iz glodavačkog IL-15 i regulacijska područja uzvodno od prvog egzona koji kodira protein iz gena za glodavački IL-15, a eksprimiranje gena za humanizirani IL-15 je pod kontrolom navedenih regulacijskih područja, i
gdje gen za humanizirani IL-15 dovodi eksprimiranja proteina IL-15 koji kada je zreo je posve ljudski.
6. Genetički modificirani glodavac u skladu s patentnim zahtjevom 5, naznačen time što je gen za humanizirani IL-15 na položaju u genomu glodavca koji nije na lokusu endogenog IL-15.
7. Genetički modificirani glodavac u skladu s patentnim zahtjevom 5 ili 6, naznačen time što je miš ili štakor.
8. Postupak dobivanja genetički modificiranog glodavca, naznačen time što se sastoji u unošenju gena za humanizirani IL-15 u glodavački genom,
gdje gen za humanizirani IL-15 sadrži egzone ljudskog IL-15 koji kodiraju zreli protein,
gdje gen za humanizirani IL-15 kodira protein koji sadrži polipeptidni slijed zrelog ljudskog IL-15,
gdje gen za humanizirani IL-15 sadrži sve egzone koji ne kodiraju protein iz glodavačkog IL-15 i regulacijska područja uzvodno od prvog egzona koji kodira protein iz gena za glodavački IL-15, a eksprimiranje gena za humanizirani IL-15 je pod kontrolom navedenih regulacijskih područja, i
gdje gen za humanizirani IL-15 dovodi eksprimiranja proteina IL-15 koji kada je zreo je posve ljudski.
9. Postupak u skladu s patentnim zahtjevom 8, naznačen time što je gen za humanizirani IL-15 integriran u glodavački genom na položaju koji nije na lokusu endogenog IL-15.
10. Postupak u skladu s patentnim zahtjevom 8 ili 9, naznačen time što je genetički modificirani glodavac miš ili štakor.
11. Postupak identificiranja sredstva koje je antagonist ljudskog IL-15, naznačen time što se sastoji u određivanju učinka sredstva na funkciju posredovanu s ljudskim IL-15 kada se primjenjuje na genetički modificiranom glodavcu u skladu s patentnim zahtjevom 1 ili 2, te u identificiranju sredstva kao antagonista IL-15 ako ono antagonizira funkciju ljudskog IL-15 u genetički modificiranom glodavcu.
12. Postupak određivanja smanjuje li sredstvo razvoj limfocita posredovan s IL-15, naznačen time što se sastoji u:
mjerenju broja limfocita kod glodavca u jednoj ili više vremenskih točaka nakon primjene sredstva na glodavcu, i
određivanju smanjuje li sredstvo populaciju limfocit, gdje je navedeni glodavac genetički modificirani glodavac u skladu s patentnim zahtjevom 1 ili 2.
13. Postupak određivanja smanjuje li sredstvo infiltriranje limfocita posredovano s IL-15 u tkivo ili zglob, naznačen time što se sastoji u:
mjerenju infiltriranja limfocita u tkivo ili zglob u jednoj ili više vremenskih točaka nakon primjene sredstva na genetički modificiranom glodavcu u skladu s patentnim zahtjevom 1 ili 2 u određenom vremenskom periodu, i
određivanju smanjuje li sredstvo infiltriranje limfocita u tkivo ili zglob.
14. Postupak određivanja smanjuje li sredstvo napredovanje artritisa posredovano s IL-15, naznačen time što se sastoji u:
određivanju utječe li sredstvo na napredovanje artritisa kada se primjenjuje kroz određeni vremenski period na genetički modificiranom glodavcu u skladu s patentnim zahtjevom 1 ili 2, te što se dodatno sastoji u izazivanju artritisa, gdje se navedeno određivanje sastoji u mjerenju napredovanja artritisa u genetički modificiranom glodavcu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891013P | 2013-10-15 | 2013-10-15 | |
| EP16192440.2A EP3138397B1 (en) | 2013-10-15 | 2014-10-15 | Humanized il-15 animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190542T1 true HRP20190542T1 (hr) | 2019-07-26 |
Family
ID=51830649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170380TT HRP20170380T1 (hr) | 2013-10-15 | 2017-03-07 | Životinje s humaniziranim il-5 |
| HRP20190542TT HRP20190542T1 (hr) | 2013-10-15 | 2019-03-20 | Životinje s humaniziranim il-15 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170380TT HRP20170380T1 (hr) | 2013-10-15 | 2017-03-07 | Životinje s humaniziranim il-5 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9155290B2 (hr) |
| EP (3) | EP2908626B1 (hr) |
| JP (3) | JP6492095B2 (hr) |
| KR (1) | KR102376041B1 (hr) |
| CN (2) | CN105744829B (hr) |
| AU (2) | AU2014337526B2 (hr) |
| BR (1) | BR112016008175A2 (hr) |
| CA (1) | CA2926090C (hr) |
| CY (2) | CY1118675T1 (hr) |
| DK (2) | DK3138397T3 (hr) |
| ES (2) | ES2613379T3 (hr) |
| HK (1) | HK1210659A1 (hr) |
| HR (2) | HRP20170380T1 (hr) |
| HU (2) | HUE043969T2 (hr) |
| IL (2) | IL244525B (hr) |
| LT (2) | LT3138397T (hr) |
| MX (1) | MX2016004781A (hr) |
| NZ (1) | NZ718655A (hr) |
| PL (2) | PL3138397T3 (hr) |
| PT (2) | PT3138397T (hr) |
| RS (2) | RS55472B1 (hr) |
| RU (1) | RU2674910C2 (hr) |
| SG (2) | SG10201607768YA (hr) |
| SI (2) | SI3138397T1 (hr) |
| SM (1) | SMT201700024B (hr) |
| TR (1) | TR201904342T4 (hr) |
| WO (1) | WO2015057758A1 (hr) |
| ZA (1) | ZA201601676B (hr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010303737B2 (en) | 2009-10-06 | 2014-05-29 | Institute For Research In Biomedicine (Irb) | Genetically modified mice and engraftment |
| PT2675271T (pt) | 2011-02-15 | 2018-10-11 | Univ Yale | Ratinhos humanizados para m-csf |
| RU2768282C2 (ru) | 2012-09-07 | 2022-03-23 | Йель Юниверсити | Генетически модифицированные не принадлежащие к человеческому роду животные и способ их использования |
| DK3939423T3 (da) | 2012-11-05 | 2024-05-06 | Regeneron Pharma | Genetisk modificerede ikke-humane dyr og fremgangsmåder til anvendelse deraf |
| KR102376041B1 (ko) | 2013-10-15 | 2022-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 il-15 동물 |
| AU2015256299C1 (en) | 2014-05-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Humanized C5 and C3 animals |
| NO2785538T3 (hr) | 2014-05-07 | 2018-08-04 | ||
| RU2711744C1 (ru) | 2014-05-19 | 2020-01-21 | Ридженерон Фармасьютикалз, Инк. | Генетически модифицированные животные, отличные от человека, экспрессирующие epo человека |
| FI3850946T3 (fi) | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni |
| RU2020124128A (ru) | 2015-04-13 | 2020-09-22 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные мыши с нокином sirpa-il15 и способы их использования |
| EP3411392B1 (en) | 2016-02-04 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| EP3476865B1 (en) | 2016-06-28 | 2023-09-13 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Method for constructing pd-1 gene-modified humanized animal model and use thereof |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| US11317611B2 (en) | 2016-08-31 | 2022-05-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric PD-L1 |
| WO2018041121A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ctla-4 |
| CN107815468B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018086594A1 (en) | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tim-3 |
| CN108070613B (zh) | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN108239659B (zh) | 2016-12-23 | 2020-03-03 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN108424928B (zh) | 2016-12-30 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| CN109136274B (zh) | 2017-06-19 | 2021-04-23 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd40基因改造动物模型的制备方法及应用 |
| CN109136275B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化gitr基因改造动物模型的制备方法及应用 |
| CN109136261B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化cd28基因改造动物模型的制备方法及应用 |
| US20200236916A1 (en) * | 2017-08-09 | 2020-07-30 | The Jackson Laboratory | Immunodeficient mice expressing human interleukin 15 |
| WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| CN109913493B (zh) | 2017-12-12 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd3基因改造动物模型的制备方法及应用 |
| KR20210031868A (ko) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Ditra 질환의 비인간 동물 모델 및 이의 용도 |
| CN111057721B (zh) | 2018-10-12 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用 |
| WO2020125763A1 (en) | 2018-12-20 | 2020-06-25 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric lag3 |
| CN111304248B (zh) | 2018-12-25 | 2021-08-24 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子il15基因改造非人动物的构建方法及应用 |
| CN114107385A (zh) * | 2019-01-17 | 2022-03-01 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
| WO2020206139A1 (en) | 2019-04-04 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| JP2022534867A (ja) | 2019-06-04 | 2022-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法 |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| WO2021129766A1 (zh) * | 2019-12-25 | 2021-07-01 | 江苏集萃药康生物科技股份有限公司 | 一种il-15人源化小鼠模型及其用途 |
| AU2021212668A1 (en) * | 2020-01-28 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized PNPLA3 locus and methods of use |
| CN111485001A (zh) * | 2020-04-14 | 2020-08-04 | 澎立生物医药技术（上海）有限公司 | 具有nk细胞及adcc能力的人源化免疫系统小鼠的构建方法 |
| CN112481303B (zh) * | 2021-02-09 | 2021-05-25 | 百奥赛图(北京)医药科技股份有限公司 | Il15ra基因人源化非人动物及其构建方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001239750A1 (en) | 2000-02-08 | 2001-08-20 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the interleukin 15 gene |
| US7759541B2 (en) * | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| PL1899364T3 (pl) * | 2005-05-17 | 2020-08-24 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP3456190B1 (en) * | 2008-06-27 | 2021-11-24 | Merus N.V. | Antibody producing transgenic murine animal |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| AU2010303737B2 (en) | 2009-10-06 | 2014-05-29 | Institute For Research In Biomedicine (Irb) | Genetically modified mice and engraftment |
| AU2010339863B2 (en) * | 2009-12-21 | 2014-07-17 | Regeneron Pharmaceuticals, Inc. | Humanized FcyR mice |
| PT2675271T (pt) | 2011-02-15 | 2018-10-11 | Univ Yale | Ratinhos humanizados para m-csf |
| KR101926442B1 (ko) * | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스 |
| EP4311833A3 (en) | 2011-10-28 | 2024-05-01 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US9043996B2 (en) * | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| EP2818478B1 (en) | 2011-10-28 | 2017-02-01 | Regeneron Pharmaceuticals, Inc. | Humanized IL-6 and IL-6 receptor |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| RU2768282C2 (ru) | 2012-09-07 | 2022-03-23 | Йель Юниверсити | Генетически модифицированные не принадлежащие к человеческому роду животные и способ их использования |
| DK3939423T3 (da) | 2012-11-05 | 2024-05-06 | Regeneron Pharma | Genetisk modificerede ikke-humane dyr og fremgangsmåder til anvendelse deraf |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| IL297607B2 (en) | 2013-09-23 | 2024-01-01 | Regeneron Pharma | Non-human animals with a humanized gene for SIGNAL-REGULATORY PROTEIN |
| KR102376041B1 (ko) | 2013-10-15 | 2022-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 il-15 동물 |
-
2014
- 2014-10-15 KR KR1020167009228A patent/KR102376041B1/ko active IP Right Grant
- 2014-10-15 WO PCT/US2014/060568 patent/WO2015057758A1/en active Application Filing
- 2014-10-15 RS RS20161140A patent/RS55472B1/sr unknown
- 2014-10-15 PL PL16192440T patent/PL3138397T3/pl unknown
- 2014-10-15 EP EP14790452.8A patent/EP2908626B1/en active Active
- 2014-10-15 DK DK16192440.2T patent/DK3138397T3/en active
- 2014-10-15 RS RS20190349A patent/RS58465B1/sr unknown
- 2014-10-15 HU HUE16192440A patent/HUE043969T2/hu unknown
- 2014-10-15 US US14/514,454 patent/US9155290B2/en active Active
- 2014-10-15 CN CN201480056455.3A patent/CN105744829B/zh active Active
- 2014-10-15 ES ES14790452.8T patent/ES2613379T3/es active Active
- 2014-10-15 BR BR112016008175A patent/BR112016008175A2/pt not_active Application Discontinuation
- 2014-10-15 RU RU2016116847A patent/RU2674910C2/ru active
- 2014-10-15 EP EP18206034.3A patent/EP3461331A1/en not_active Withdrawn
- 2014-10-15 PT PT16192440T patent/PT3138397T/pt unknown
- 2014-10-15 LT LTEP16192440.2T patent/LT3138397T/lt unknown
- 2014-10-15 LT LTEP14790452.8T patent/LT2908626T/lt unknown
- 2014-10-15 CA CA2926090A patent/CA2926090C/en active Active
- 2014-10-15 TR TR2019/04342T patent/TR201904342T4/tr unknown
- 2014-10-15 JP JP2016549191A patent/JP6492095B2/ja active Active
- 2014-10-15 PT PT147904528T patent/PT2908626T/pt unknown
- 2014-10-15 SG SG10201607768YA patent/SG10201607768YA/en unknown
- 2014-10-15 MX MX2016004781A patent/MX2016004781A/es unknown
- 2014-10-15 SI SI201431130T patent/SI3138397T1/sl unknown
- 2014-10-15 HU HUE14790452A patent/HUE033272T2/en unknown
- 2014-10-15 PL PL14790452T patent/PL2908626T3/pl unknown
- 2014-10-15 SG SG11201601828XA patent/SG11201601828XA/en unknown
- 2014-10-15 CN CN201810808707.3A patent/CN109090037B/zh active Active
- 2014-10-15 AU AU2014337526A patent/AU2014337526B2/en active Active
- 2014-10-15 EP EP16192440.2A patent/EP3138397B1/en active Active
- 2014-10-15 DK DK14790452.8T patent/DK2908626T3/en active
- 2014-10-15 SI SI201430109T patent/SI2908626T1/sl unknown
- 2014-10-15 NZ NZ718655A patent/NZ718655A/en unknown
- 2014-10-15 ES ES16192440T patent/ES2715949T3/es active Active
-
2015
- 2015-09-01 US US14/842,342 patent/US20150366175A1/en not_active Abandoned
- 2015-11-20 HK HK15111500.3A patent/HK1210659A1/xx unknown
-
2016
- 2016-03-10 IL IL24452516A patent/IL244525B/en active IP Right Grant
- 2016-03-10 ZA ZA2016/01676A patent/ZA201601676B/en unknown
-
2017
- 2017-01-04 CY CY20171100008T patent/CY1118675T1/el unknown
- 2017-01-16 SM SM201700024T patent/SMT201700024B/it unknown
- 2017-03-07 HR HRP20170380TT patent/HRP20170380T1/hr unknown
- 2017-12-06 US US15/832,976 patent/US10561125B2/en active Active
-
2018
- 2018-10-16 JP JP2018194898A patent/JP6600061B2/ja active Active
-
2019
- 2019-03-18 CY CY20191100323T patent/CY1121405T1/el unknown
- 2019-03-20 HR HRP20190542TT patent/HRP20190542T1/hr unknown
- 2019-10-03 JP JP2019182817A patent/JP2019216750A/ja active Pending
- 2019-10-10 IL IL269907A patent/IL269907B/en active IP Right Grant
-
2020
- 2020-01-02 US US16/732,400 patent/US11503813B2/en active Active
- 2020-12-08 AU AU2020286186A patent/AU2020286186B2/en active Active
-
2022
- 2022-10-17 US US18/047,014 patent/US20230189772A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190542T1 (hr) | Životinje s humaniziranim il-15 | |
| HRP20190634T1 (hr) | Životinje koje nisu ljudi, koje imaju humanizirani gen 47 iz razlikovnog grozda | |
| Chen et al. | Broad distribution of hepatocyte proliferation in liver homeostasis and regeneration | |
| HRP20231121T1 (hr) | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale | |
| SI3027015T1 (en) | HUMANIZED IL-4 AND IL-4R ALPHA ANIMALS | |
| HRP20200294T1 (hr) | Miševi s adam6 | |
| Park et al. | Calcium channel functions in pain processing | |
| Riccio et al. | Ret and Etv4 promote directed movements of progenitor cells during renal branching morphogenesis | |
| Werth et al. | Transcription factor TFCP2L1 patterns cells in the mouse kidney collecting ducts | |
| Mould et al. | Blimp1/Prdm1 governs terminal differentiation of endovascular trophoblast giant cells and defines multipotent progenitors in the developing placenta | |
| Eng et al. | Zebrafish facial lymphatics develop through sequential addition of venous and non‐venous progenitors | |
| BR112018010158A2 (pt) | roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga | |
| HRP20200899T1 (hr) | Neljudske životinje koje imaju humanizirane fc-gamma receptore | |
| MX2019004871A (es) | Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos. | |
| MX2016014504A (es) | Animales c5 y c3 humanizados. | |
| BR112015004696A2 (pt) | polipeptídeos quiméricos tendo especificidade de ligação alvejada | |
| Page et al. | Positive feedback defines the timing, magnitude, and robustness of angiogenesis | |
| Lee et al. | Mouse models of syndromic craniosynostosis | |
| MA55527A (fr) | Polynucléotides, compositions et procédés d'expression de polypeptides | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| Hirschberger et al. | Conserved and unique transcriptional features of pharyngeal arches in the skate (Leucoraja erinacea) and evolution of the jaw | |
| Harder et al. | ZNF423: transcriptional modulation in development and cancer | |
| Coutaud et al. | Characterization of a novel transgenic mouse line expressing Cre recombinase under the control of the Cdx2 neural specific enhancer | |
| Bhattacharya et al. | Connexin 43 gap junctional intercellular communication inhibits evx1 expression and joint formation in regenerating fins | |
| JP2016506945A5 (hr) |